Topical Astodrimer Sodium, a Non-Toxic Polyanionic Dendrimer, Demonstrates Antiviral Activity in an Experimental Ocular Adenovirus Infection Model
Open Access
- 5 June 2021
- Vol. 26 (11), 3419
- https://doi.org/10.3390/molecules26113419
Abstract
There is no approved antiviral therapy for adenovirus (HAdV) ocular infections. Astodrimer sodium (SPL7013) is a polyanionic dendrimer with antiviral activity. The current study evaluated the ocular tolerability and anti-adenoviral efficacy of topical SPL7013 in rabbit ocular models. In a tolerability study, rabbits were treated with 3% SPL7013, vehicle, or 0.5% cidofovir. Their eyes were graded using the Draize scale. In antiviral efficacy studies, HAdV5 inoculated eyes were treated with 3% SPL7013, vehicle, or 0.5% cidofovir. Eyes were cultured for the virus on days 0, 1, 3, 4, 5, 7, 9, 11, and 14. Viral titers were determined. There were no differences in Draize scores between 3% SPL7013 and vehicle on any day. Cidofovir produced significantly higher Draize scores on day 12 than SPL7013 and vehicle. The 3% SPL7013 and 0.5% cidofovir significantly reduced daily viral titers and positive cultures per total compared with vehicle on several different days. The 3% SPL7013 and 0.5% cidofovir significantly reduced the duration of HAdV5 shedding compared to vehicle. The 3% SPL7013 demonstrated significantly more antiviral activity compared with vehicle in the Ad5/NZW rabbit ocular model. The 3% SPL7013 induced “minimal” to “practically non-irritating” Draize scores in the ocular tolerability study. Further development of astodrimer sodium as a topical antiviral therapy for adenoviral ocular infections is indicated.Keywords
Funding Information
- Starpharma Pty Ltd (None, None, EY08098)
- Allergan (None)
- Research to Prevent Blindness (None)
This publication has 25 references indexed in Scilit:
- Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004)AIDS, 2011
- Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1Antiviral Research, 2011
- A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 DaysPLOS ONE, 2011
- Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral ActivityPLOS ONE, 2010
- The In Vitro and In Vivo Evaluation of ddC as a Topical Antiviral for Ocular Adenovirus InfectionsInvestigative Opthalmology & Visual Science, 2009
- Efficacy of Topical Immunoglobulins against Experimental Adenoviral Ocular InfectionPublished by Association for Research in Vision and Ophthalmology (ARVO) ,2007
- Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex virusesAntiviral Research, 2005
- SPL7013 Gel as a Topical Microbicide for Prevention of Vaginal Transmission of SHIV89.6Pin MacaquesAIDS Research and Human Retroviruses, 2005
- Pretreatment with Topical 0.1% (S)-1 -(3-hydroxy-2-phosphonylmethoxypropyl)cytosine Inhibits Adenovirus Type 5 Replication in the New Zealand Rabbit Ocular ModelCornea, 1992
- Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitroAntiviral Research, 1991